AUS
NZ
UK
CA
USA
IND
Highlights:
- Narrowed Losses: ValiRx reported a comprehensive loss of £0.97 million, an improvement from the previous year’s loss.
- Operational Milestones: The company signed its first U.S. customer and expanded its Inaphaea Biobank to include advanced patient-derived models.
- Strategic Collaborations: Partnerships with DefiniGen and Dundee University were established, focusing on innovative cancer research projects.
ValiRx (LSE:VAL), a life science firm focused on the development of cancer therapeutics, announced a total comprehensive loss of £0.97 million for the six months ending 30 June, representing a slight narrowing from the loss of £1.04 million recorded during the same period last year. The AIM-traded company also reported a decrease in its loss before income tax, which fell to £1.05 million from £1.15 million in the prior year.
Research and development expenses, excluding employee-related costs, saw a reduction to £0.12 million from £0.21 million. Meanwhile, administrative expenses remained stable at approximately £0.95 million, reflecting the company's ongoing commitment to maintaining operational efficiency. By the end of June, ValiRx reported cash and cash equivalents of £0.81 million.
On the operational front, ValiRx achieved significant milestones, including signing its first U.S. customer for its Inaphaea tCRO service. This agreement marks a crucial step in expanding its service offerings in the competitive U.S. market. Additionally, the company announced the expansion of its Inaphaea Biobank, now including two-dimensional (2D) and three-dimensional (3D) patient-derived cell models. This enhancement is expected to bolster ValiRx's research capabilities and strengthen its position in the industry.
Furthermore, collaboration agreements have been established with DefiniGen and Dundee University, with the latter launching a pro-senescence project aimed at advancing cancer therapies. ValiRx also commenced a second evaluation project in partnership with Imperial College, focusing on drug-resistant ovarian cancer, while continuing its assessment of Cytolytix for prostate cancer in collaboration with the Open University.
The operational advancements and strategic partnerships highlight ValiRx’s ongoing efforts to innovate in cancer treatment and expand its market reach. As the company moves forward, these initiatives are expected to play a pivotal role in its growth strategy and development pipeline.
As of the latest trading update, ValiRx shares were down by 16.76%, trading at 1.42 pence.
